Health Care·Biotechnology·$5.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.39 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.39 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management's commentary indicated a commitment to advancing their pipeline. However, they did not provide any forward-looking guidance.
Management did not provide specific guidance for future quarters.
The company is focused on its ongoing research and development efforts.
Scholar Rock's earnings report showed a loss per share of $1.39, which was in line with expectations, but no revenue figures were provided. The stock reacted positively, increasing by 1.84%, likely due to investor optimism about the company's ongoing research initiatives despite the lack of specific guidance. Overall, the market seems to be maintaining confidence in Scholar Rock's long-term potential.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
WILLIS TOWERS WATSON
Aug 6, 2018